167 related articles for article (PubMed ID: 35963895)
21. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.
Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M
Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415
[TBL] [Abstract][Full Text] [Related]
23. An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.
Yeung YA; Krishnamoorthy V; Dettling D; Sommer C; Poulsen K; Ni I; Pham A; Chen W; Liao-Chan S; Lindquist K; Chin SM; Chunyk AG; Hu W; Sasu B; Chaparro-Riggers J; Djuretic I
Mol Ther; 2020 Mar; 28(3):889-900. PubMed ID: 31981494
[TBL] [Abstract][Full Text] [Related]
24. Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
Bonnevaux H; Guerif S; Albrecht J; Jouannot E; De Gallier T; Beil C; Lange C; Leuschner WD; Schneider M; Lemoine C; Caron A; Amara C; Barrière C; Siavellis J; Bardet V; Luna E; Agrawal P; Drake DR; Rao E; Wonerow P; Carrez C; Blanc V; Hsu K; Wiederschain D; Fraenkel PG; Virone-Oddos A
Oncoimmunology; 2021; 10(1):1945803. PubMed ID: 34484869
[TBL] [Abstract][Full Text] [Related]
25. A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
Riillo C; Polerà N; Di Martino MT; Juli G; Hokanson CA; Odineca T; Signorelli S; Grillone K; Ascrizzi S; Mancuso A; Staropoli N; Caparello B; Cerra M; Nisticò G; Tagliaferri P; Crea R; Caracciolo D; Tassone P
J Transl Med; 2023 May; 21(1):301. PubMed ID: 37143061
[TBL] [Abstract][Full Text] [Related]
26. A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART
Betts A; Haddish-Berhane N; Shah DK; van der Graaf PH; Barletta F; King L; Clark T; Kamperschroer C; Root A; Hooper A; Chen X
AAPS J; 2019 May; 21(4):66. PubMed ID: 31119428
[TBL] [Abstract][Full Text] [Related]
27. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
28. Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy.
Xie F; Zhang L; Shi S; Zheng A; Di J; Jin S; Miao X; Wu F; Chen X; Zhang Y; Wei X; Xu Y
MAbs; 2022; 14(1):2115205. PubMed ID: 36041060
[TBL] [Abstract][Full Text] [Related]
29. Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
Huang L; Xie K; Li H; Wang R; Xu X; Chen K; Gu H; Fang J
Drug Des Devel Ther; 2020; 14():3201-3214. PubMed ID: 32982167
[TBL] [Abstract][Full Text] [Related]
30. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
[TBL] [Abstract][Full Text] [Related]
31. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
[TBL] [Abstract][Full Text] [Related]
33. Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors.
Xu G; Qian N; Liu Y; Li H; Yang C; Wang J; Wang F; Chen L; Bai G; Xu Q; Pan X; Gao X
Immunobiology; 2022 Nov; 227(6):152283. PubMed ID: 36198215
[TBL] [Abstract][Full Text] [Related]
34. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
Smith EJ; Olson K; Haber LJ; Varghese B; Duramad P; Tustian AD; Oyejide A; Kirshner JR; Canova L; Menon J; Principio J; MacDonald D; Kantrowitz J; Papadopoulos N; Stahl N; Yancopoulos GD; Thurston G; Davis S
Sci Rep; 2015 Dec; 5():17943. PubMed ID: 26659273
[TBL] [Abstract][Full Text] [Related]
35. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
36. A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.
Boustany LM; LaPorte SL; Wong L; White C; Vinod V; Shen J; Yu W; Koditek D; Winter MB; Moore SJ; Mei L; Diep L; Huang Y; Liu S; Vasiljeva O; West J; Richardson J; Irving B; Belvin M; Kavanaugh WM
Cancer Res; 2022 Nov; 82(22):4288-4298. PubMed ID: 36112781
[TBL] [Abstract][Full Text] [Related]
37. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
Chu F; Cao J; Liu J; Yang H; Davis TJ; Kuang SQ; Cheng X; Zhang Z; Karri S; Vien LT; Bover L; Sun R; Vega F; Green M; Davis RE; Neelapu SS
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007239
[TBL] [Abstract][Full Text] [Related]
39. Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.
Tian Z; Shi C; Yang G; Allen JK; Shi Q; Al-Shami A; Olson JW; Smith MG; Chang Q; Kaur J; You J; Lofton TE; Gonzalez MA; Zhang Q; Zha D; Tasian SK; Jain N; Konopleva MY; Heffernan T; Molldrem JJ
Leukemia; 2023 Oct; 37(10):2006-2016. PubMed ID: 37634013
[TBL] [Abstract][Full Text] [Related]
40. Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity.
Faber ML; Oldham RAA; Thakur A; Rademacher MJ; Kubicka E; Dlugi TA; Gifford SA; McKillop WM; Schloemer NJ; Lum LG; Medin JA
Front Immunol; 2023; 14():1225610. PubMed ID: 37646042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
